1,121
Views
8
CrossRef citations to date
0
Altmetric
Letters to the Editor

Irreversible ototoxicity associated with the use of erlotinib in a patient with pancreatic cancer

, , , , &
Pages 1171-1173 | Received 07 May 2008, Published online: 08 Jul 2009

References

  • Sandler AB. Nondermatologic adverse events associated with anti-EGFR therapy. Oncology (Williston Park) 2006; 20: 35–40
  • Hume CR, Kirkegaard M, Oesterle EC. ErbB expression: The mouse inner ear and maturation of the mitogenic response to heregulin. J Assoc Res Otolaryngol 2003; 4: 422–43
  • Stankovic K, Rio C, Xia A, Sugawara M, Adams JC, Liberman MC, et al. Survival of adult spiral ganglion neurons requires erbB receptor signaling in the inner ear. J Neurosci 2004; 24: 8651–61
  • Lambert PR. Inner ear hair cell regeneration in a mammal: Identification of a triggering factor. Laryngoscope 1994; 104: 701–18
  • Yamashita H, Oesterle EC. Induction of cell proliferation in mammalian inner-ear sensory epithelia by transforming growth factor alpha and epidermal growth factor. Proc Nat Acad Sci USA 1995; 92: 3152–5
  • Kuntz AL, Oesterle EC. Transforming growth factor alpha with insulin stimulates cell proliferation in vivo in adult rat vestibular sensory epithelium. J Comp Neurol 1998; 399: 413–23
  • Zine A, de Ribaupierre F. Tissue-specific levels and cellular distribution of epidermal growth factor receptors within control and neomycin-damaged neonatal rat Organ of Corti. J Neurobiol 1999; 38: 313–22
  • Zine A, Nyffeler M, de Ribaupierre F. Spatial expression patterns of epidermal growth factor receptor gene transcripts in the postnatal mammalian cochlea. Hear Res 2000; 14: 19–27
  • Attili VS, Bapsy PP, Anupama G, Lokanatha D. Irreversible sensorineural hearing loss due to Imatinib. Leuk Res 2008; 32: 991–2
  • Chim CS, Wong LG. Deafness associated with the use of Bortezomib in multiple myeloma. Acta Oncol 2008; 47: 323–4

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.